Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor Research Institute and Sammons Cancer, Dallas Texas, USA.
Baylor Institute for Immunology Research, Dallas, Texas, USA.
JCI Insight. 2019 Mar 21;4(6). doi: 10.1172/jci.insight.125294.
Chemoresistance in cancer is linked to a subset of cancer cells termed "cancer stem cells" (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer (CRC). CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. Inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and resensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ spheroid-derived CSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS and DFS in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, and this was in part orchestrated by a distinct panel of miRNAs with dysregulated profiles. These findings suggest that specific miRNAs could serve as therapeutic targets as well as promising prognostic biomarkers in patients with colorectal neoplasia.
癌症的化疗耐药性与被称为“癌症干细胞”(CSC)的一小部分癌细胞有关,特别是那些表达 CD44 变体的细胞似乎代表了更具侵袭性的疾病表型。在此,我们证明 CD44v6 代表了具有更高化疗药物耐药性的 CSC 群体,其高表达与结直肠癌(CRC)患者的总生存(OS)和无病生存(DFS)不良密切相关。CD44v6+细胞对化疗药物表现出更高的耐药性,并且具有显著高的肿瘤起始能力。抑制 CD44v6 导致自我更新能力减弱和对化疗药物的重新敏感化。值得注意的是,CD44v6+球体衍生的 CSCs 的 miRNA 谱分析确定了一组独特的 miRNA 面板,表明具有高自我更新能力。特别是,miR-1246 在 CD44v6+细胞中过表达,并与 CRC 患者的 OS 和 DFS 不良相关。我们证明 CD44v6+CSC 诱导 CRC 细胞的化疗耐药性并增强其致瘤性,这部分是由失调表达谱的独特 miRNA 面板协调的。这些发现表明,特定的 miRNA 可以作为治疗靶点,并作为结直肠肿瘤患者有前途的预后生物标志物。